Core B: University of Kentucky Alzheimer's Disease Core Center

核心 B：肯塔基大学阿尔茨海默病核心中心

• 批准号: 10662342
• 负责人: GREGORY A JICHA
• 金额: $ 94.73万
• 依托单位: UNIVERSITY OF KENTUCKY
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-08-01 至 2026-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10662342
• 关键词: Alzheimer' s Disease; Alzheimer' s Disease Core Center; Alzheimer' s disease related dementia; Area; Automobile Driving; Autopsy; Biological Markers; Brain; Clinic; Clinical; Clinical Trials; Cognitive; Collaborations; Communities; Correlative Study; Dementia; Development; Diagnosis; Disease; Education; Elderly; Enrollment; Environment; Etiology; Family; Fostering; Frontotemporal Lobar Degenerations; Funding; Genetic; Goals; Heterogeneity; Image; Individual; Industry; Infrastructure; Intervention; Kentucky; Link; Liquid substance; Longitudinal cohort; Measures; Minority; Minority Groups; Mission; Participant; Pathologic; Pharmaceutical Preparations; Phase; Phenotype; Play; Prevention; Productivity; Publications; Recommendation; Research; Research Personnel; Research Project Grants; Research Support; Role; Syndrome; System; Trademark; United States National Institutes of Health; Universities; Work; clinical phenotype; cohort; design; driving force; high risk; innovation; minority engagement; multidisciplinary; normal aging; novel; novel therapeutic intervention; parity; pre-clinical; preclinical study; research clinical testing; success; therapeutic development; translational therapeutics

Project Summary/Abstract: Clinical Core The Clinical Core of the UK-ADRC maintains a well-characterized, community-based cohort focused on normal aging and early transitional disease states and follows individuals longitudinally until brain autopsy. We maintain a mandatory autopsy requirement for all subjects (with the exception of our Minority Gateway Clinic, where autopsy is promoted but not required), allowing major contributions in the area of clinical- pathological correlative studies, and definition of early preclinical and pre-dementia disease states. These efforts have been a driving force in our recognition of the heterogeneity of community-acquired dementia, including major contributions to the field in regard to LATE, PART, VCID, and the role these pathologic states play in conjunction with traditional AD, LBD, and FTLD disease states. A major focus of our work has also been on defining early clinical transitions involving the interplay of these disease states that has driven the widespread exploration of late-life multi-etiology dementia syndromes. To further such advances, the UK-ADRC Clinical Core emphasizes deep clinical, biomarker, genetic, and post-mortem phenotyping of a diverse cohort of elderly subjects at high risk for multi-etiology dementia. Major initiatives in the area of AD mimics and transitions from normal to late-life multi-etiology dementia are well-poised to continue to move the field forward in the areas of both diagnosis and translational interventional discoveries. We have introduced exciting new initiatives in our expansion of antemortem biomarker research allowing an even deeper clinical phenotyping of our participants as we work towards translational discoveries for multi-etiology dementia. The UK-ADRC will continue to constantly evolve in dynamic ways through our proposed specific aims. Aim 1: Maintain & longitudinally characterize a central longitudinal cohort enrolling cognitively normal subjects to facilitate our understanding of preclinical disease and early cognitive transitions to multi-etiology MCI & dementia. Aim 2: Maintain and expand our successful Minority Gateway Clinics to maintain and grow our (significantly) above-parity for population minority engagement. Aim 3: Further develop and maintain an infrastructure to support translational therapeutic development through all clinical trial phases in support of NIH, ADCS, ACTC initiatives, industry-sponsored drug trials, and investigator-initiated projects. Aim 4: Foster education and support of research participants and families to ensure that our efforts are clinically meaningful, both in novel prevention studies as well as treatment in established disease Overall, the Clinical Core will continue to provide an infrastructure and environment that will continue to contribute to our success in advancing multidisciplinary, innovative AD research supporting our center theme of Transitions from Normal to Late-Life Multi-Etiology Dementia.

项目总结/摘要：临床核心 英国ADRC的临床核心保持了一个特征良好的、以社区为基础的队列，重点是 正常衰老和早期过渡性疾病状态，并纵向跟踪个体直到脑尸检。 我们对所有受试者保持强制性尸检要求（少数民族网关除外 诊所，提倡尸检，但不要求尸检），允许在临床领域作出重大贡献- 病理学相关研究，以及早期临床前和痴呆前疾病状态的定义。这些 努力是我们认识到社区获得性痴呆的异质性的驱动力， 包括对LATE、PART、VCID领域的主要贡献，以及这些病理性疾病的作用。 国家发挥与传统的AD，LBD，FTLD疾病状态。我们工作的一个主要重点是 我也一直在定义早期临床过渡，涉及这些疾病状态的相互作用， 对老年多病因痴呆综合征的广泛探索。为了进一步推动这些进展， UK-ADRC临床核心强调了一个人的深层临床，生物标志物，遗传和死后表型。 多病因痴呆高危老年受试者的不同队列。AD领域的主要举措 从正常到晚期多病因痴呆的模拟和过渡是很好的准备继续移动， 在诊断和转化介入发现领域的前沿领域。我们引进了 我们在扩大生前生物标志物研究方面的令人兴奋的新举措， 我们的参与者的表型，因为我们致力于多病因痴呆症的转化发现。的 UK-ADRC将继续通过我们提出的具体目标不断发展。 目的1：维持和纵向表征招募认知正常受试者的中心纵向队列 促进我们对临床前疾病和早期认知向多病因MCI的转变的理解， 痴呆 目标2：维持和扩大我们成功的少数民族门户诊所，以维持和发展我们的（显着） 在少数民族人口参与方面高于均等。 目标3：进一步发展和维护基础设施，以支持转化治疗开发， 支持NIH、ADCS、ACTC倡议、行业赞助的药物试验的所有临床试验阶段，以及 发起的项目。 目标4：促进对研究参与者和家庭的教育和支持，以确保我们的努力 在新的预防研究以及已确立疾病的治疗中均具有临床意义 总体而言，临床核心将继续提供基础设施和环境， 有助于我们在推进多学科，创新AD研究支持我们的中心主题的成功 从正常到晚年多病因痴呆症的转变。